SLC35C1

Across TCGA pan-cancer cohorts, SLC35C1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLC35C1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC35C1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35C1 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where SLC35C1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35C1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	+1.079	<.001	9	view →
HNSC	Male	III,IV	−0.784	<.001	8	view →
LSCC	Male	III,IV	+0.869	<.001	7	view →
CCRCC	Male	III,IV	+0.623	<.001	6	view →
COAD	All	All	+0.316	.014	3	view →
PDAC	Male	All	−0.410	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLC35C1–LUAD

Open the LUAD breakdown →